Literature DB >> 16362886

Colonic bacterial infection abrogates eosinophilic pulmonary disease.

Andrew E Williams1, Lorna Edwards, Tracy Hussell.   

Abstract

Induction of immunity to one pathogen in the lungs modifies the microenvironment and alters immunopathological changes that result from a second, unrelated pulmonary infection. However, it is unclear whether immunity generated at distant sites also affects lung immune responses. Here, we show that infection with the gut-restricted bacterium Citrobacter rodentium modifies immunopathological changes that result from pulmonary Cryptococcus neoformans infection. Th2 cytokine-driven pulmonary eosinophilia induced by C. neoformans infection was reduced, and the enhanced Th1 cytokine environment afforded more-rapid clearance of the fungus in C. rodentium-immune mice. The activated and intraepithelial (CD103+) T cell populations that expand after C. neoformans infection were diminished in C. rodentium-immune mice. T cell cross-reactivity was absent, but cross-reactive antibodies were detected. It is of importance to the "hygiene hypothesis" that these data indicate that an immune response induced by a gut-restricted pathogen can modify the immune outcome after pulmonary infection, suggesting that cell-phenotype modifications occur across mucosal sites.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16362886     DOI: 10.1086/498915

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

Review 1.  The impact of successive infections on the lung microenvironment.

Authors:  Arnaud Didierlaurent; John Goulding; Tracy Hussell
Journal:  Immunology       Date:  2007-12       Impact factor: 7.397

Review 2.  Respiratory infections: do we ever recover?

Authors:  John Goulding; Robert Snelgrove; José Saldana; Arnaud Didierlaurent; Mary Cavanagh; Emily Gwyer; Jeremy Wales; Erika L Wissinger; Tracy Hussell
Journal:  Proc Am Thorac Soc       Date:  2007-12

3.  Virally delivered cytokines alter the immune response to future lung infections.

Authors:  James Harker; Alexander Bukreyev; Peter L Collins; Belinda Wang; Peter J M Openshaw; John S Tregoning
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

4.  The intestinal microbiota and viral susceptibility.

Authors:  Julie K Pfeiffer; Justin L Sonnenburg
Journal:  Front Microbiol       Date:  2011-04-27       Impact factor: 5.640

5.  Virus-like particle-induced protection against MRSA pneumonia is dependent on IL-13 and enhancement of phagocyte function.

Authors:  Agnieszka Rynda-Apple; Erin Dobrinen; Mark McAlpine; Amanda Read; Ann Harmsen; Laura E Richert; Matthew Calverley; Kyler Pallister; Jovanka Voyich; James A Wiley; Ben Johnson; Mark Young; Trevor Douglas; Allen G Harmsen
Journal:  Am J Pathol       Date:  2012-05-26       Impact factor: 4.307

6.  H. pylori-infection and antibody immune response in a rural Tanzanian population.

Authors:  Sam M Mbulaiteye; Benjamin D Gold; Ruth M Pfeiffer; Glen R Brubaker; John Shao; Robert J Biggar; Michie Hisada
Journal:  Infect Agent Cancer       Date:  2006-09-14       Impact factor: 2.965

7.  Human β-Defensin 2 Mutations Are Associated With Asthma and Atopy in Children and Its Application Prevents Atopic Asthma in a Mouse Model.

Authors:  Natascha S Borchers; Elisangela Santos-Valente; Antoaneta A Toncheva; Jan Wehkamp; Andre Franke; Vincent D Gaertner; Peter Nordkild; Jon Genuneit; Benjamin A H Jensen; Michael Kabesch
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

8.  Differential Type I Interferon Signaling Is a Master Regulator of Susceptibility to Postinfluenza Bacterial Superinfection.

Authors:  Kelly M Shepardson; Kyle Larson; Rachelle V Morton; Justin R Prigge; Edward E Schmidt; Victor C Huber; Agnieszka Rynda-Apple
Journal:  MBio       Date:  2016-05-03       Impact factor: 7.867

Review 9.  Manipulation of acute inflammatory lung disease.

Authors:  E L Wissinger; J Saldana; A Didierlaurent; T Hussell
Journal:  Mucosal Immunol       Date:  2008-05-07       Impact factor: 7.313

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.